- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sun Pharmaceutical Industries Ltd.
Headquarters: Mumbai, Maharshtra, India
Website: http://www.sunpharma.com
Year Founded: 1983
Status: Public
Industry Sector: HealthTechnology
CEO: Dilip Shantilal Shanghvi
Number Of Employees: 25,894
Enterprise Value: $45,143,266,152
PE Ratio: 35.67
Exchange/Ticker 1: NSE:SUNPHARMA
Exchange/Ticker 2: BSE:524715
Latest Market Cap: $47,907,539,957
BioCentury | Apr 29, 2025
Guest Commentary
The modern biotech chief commercial officer: skills for success — a Guest Commentary
The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Aug 13, 2024
Data Byte
Summer lull as FDA approves only 2 NMEs in July
Total for the year stands at 26, lagging last year
BioCentury | May 6, 2024
Management Tracks
Pfizer taps Citi’s Baum for C-level pipeline management and strategy role
Plus: Radiotherapy play Ratio gets new COO, CFO; and updates from Araceli, Kezar and Hercules
BioCentury | Apr 6, 2024
Finance
Public equity report: Contineum’s NASDAQ listing, Oruka’s financing-merger combo
Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM
BioCentury | Jan 23, 2024
Deals
Deals roundup: Coherus sharpens oncology focus, BridgeBio bolsters balance sheet and more
BioCentury’s weekly roundup of biopharma deals, Jan. 16-22
BioCentury | Dec 23, 2023
Regulation
Dec. 22 Quick Takes: Sarepta seeking expanded label, full approval of DMD gene therapy
Plus: June PDUFA date for Daiichi-Merck ADC, and updates from Lyndra, ImpriMed, Mundipharma and Novamab
BioCentury | Jan 19, 2023
Deals
Building dermatology franchise, Sun buys Concert in latest CVR deal
With cash running short, 17-year-old Concert accepts offer for $576M up front as it finally neared commercial stage
BioCentury | Jul 27, 2022
Deals
July 26 Quick Takes: Merck, Kelun enter second development deal
Plus BridgeBio falls after achondroplasia Phase II data and updates from AbbVie, Aurinia and CEPI
BioCentury | May 18, 2022
Management Tracks
Fromen to leave PacBio as CCO
Plus Vraniak joins Inversago as CFO and updates from Thabor, Glympse, Civetta and more
Items per page:
1 - 10 of 124